Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets-5

10 μg/kg/d (speckled), 30 μg/kg/d (gray), and 60 μg/kg/d (black). The time points shown represent the point of maximal increase for each parameter, as illustrated in , as follows: day 21 for increase in cell number, day 7 for Ki-67, and day 14 for bcl-2 expression. (A) Percent increase in absolute circulating cell number (per milliliter) over pretherapy value for each subset at day 21 after rhIL-7. Percent increase in the naive CD8 subset were significantly higher than for the CD8 memory (P = 0.008) or CD8 effector subsets (P = 0.008). (B) Net increase in the proportion of Ki67 cells in each subset at day 7 was calculated by subtracting the percentage of each subset that expressed Ki-67 at baseline from the percentage expressing Ki-67 at day 7 of rhIL-7 therapy. (C) Net increase in bcl-2 MFI in each subset at day 14 was calculated by subtracting the MFI of bcl-2 expression at baseline from the MFI on day 14 after rhIL-7 for each subset. See Fig. S2 for detailed data on changes in subset parameters for each dose level. (D) Net increase in cell number at day 21 in subsets defined by CCR7 and CD45RA surface expression (see Materials and methods) as follows: naive (CCR7CD45RA), central memory (CCR7CD45RA), effector memory (CCR7CD45RA), and effector RA (CCR7CD45RA). Mean value for the six studied subjects. Error bars represent the SEM. Fig S2 is available at .<p><b>Copyright information:</b></p><p>Taken from "Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets"</p><p></p><p>The Journal of Experimental Medicine 2008;205(7):1701-1714.</p><p>Published online 7 Jul 2008</p><p>PMCID:PMC2442646.</p><p>